Global PEGylated Proteins Market – Industry Trends and Forecast to 2030

 PEGylated Proteins Market Analysis and Size

According to the International Agency for Research on Cancer (IARC), new cancer cases are expected to reach 27.5 million by 2040, with 16.3 million cancer-related deaths. Aging, lifestyle choices, and economic transitions will contribute to the global burden. Furthermore, the companies actively investing in research and develop activites for new or referenced proteins as treatment drugs which will boost the growth of market.

Data Bridge Market Research analyses that the PEGylated proteins market which was USD 921.84 million in 2022, is expected to reach USD 1877.66 million by 2030, at a CAGR of 9.3% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

PEGylated Proteins Market Scope and Segmentation  

Market Definition

PEGylation is polyethylene glycol polymer chains' covalent and non-covalent attachment to molecules such as medication, therapeutic protein, or vesicle. PEGylation increases medicine stability and solubility while decreasing immunogenicity by changing the molecule's electrostatic binding, confirmation, and hydrophobicity.

Global PEGylated Proteins Market Dynamics

Drivers

• Rising prevalence of lifestyle diseases

The market is expected to expand due to the growing biologics industry, increased acceptance of protein-based medications over non-protein-based medications, and the rising prevalence of lifestyle diseases. The rising prevalence of chronic diseases such as cancer, kidney disease, and rheumatoid arthritis is propelling the PEGylated proteins market. Chronic kidney disease affects 15% of American adults, or 37 million people, according to the Centers for Disease Control and Prevention's Chronic Kidney Disease in the United States, 2021 study. The development of new therapies based on PEGylated proteins for the treatment of chronic renal disease is a priority these days. Protein-based medications are increasingly preferred over non-protein-based medications due to PEGylation, improving protein circulation, half-life, and thus efficacy.

• Rise in cancer cases

According to GLOBOCAN 2020, new cancer cases diagnosed in 2020 will account for 19,292,789 cases worldwide, with 9,958,133 cancer deaths. According to the same source, breast cancer accounted for 2,261,419 new cancer cases in 2020, lung cancer with 2,206,771 new cases, prostate cancer with 1,414,259, and colon cancer with 1,148,515 new cases. Furthermore, according to the Joint United Nations Program on HIV/AIDS (UNAIDS) fact sheet Global HIV and AIDS Statistics 2021, 37.7 million people worldwide were living with HIV in 2020. As a result of the growing global burden of chronic and infectious diseases such as cancer, HIV, tuberculosis, and others, the demand for developing medicine is expected to rise.

Opportunities

• Rising investments in biotechnology and pharmaceutical companies

Biotechnology and pharmaceutical companies are increasing their investments in research and development programmes, which is driving market growth. For instance, in March 2022, Flow Eighteen38, a protein sciences division established to facilitate and accelerate antibody characterization and protein purification projects, announced a EUR 5 million (USD 5.58 million) investment from its parent company, CRO FairJourneyBiologics S.A., in its protein production and biophysical characterization capabilities and services. Furthermore, there is a growing preference for protein-based drugs over non-protein-based drugs, and PEGylation increases the circulation and half-life of the proteins, improving efficacy. However, the market's major drawbacks are drug failure and drug recalls.

Restraints/Challenges

• Failures in drug development

Drug development is a complex and challenging process because drug development failures are common, the chances of a drug being developed during the first trial are slim. The overall failure rate in drug development is around 96%, with clinical development failing at 90%. A costly drug failure can result in site closures, job losses, and pharmaceutical companies' depleted research and development budgets. As a result, failures in drug development and rising therapeutic drug recalls may impede the growth of the PEGylated proteins market during the forecast period.

This PEGylated proteins market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the PEGylated proteins market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on the PEGylated Proteins Market

The coronavirus outbreak had no negative impact on the pegylated proteins market. For instance, according to a study published in the Journal of General Virology in 2020, low concentrations of PEG-IFN-alpha-2a that inhibit MERS-CoV replication in cell culture can inhibit SARS-CoV-2 replication. Covid-19 had little effect on the market for PEGylated proteins.

Furthermore, PEGylated proteins remain in high demand because they are considered necessities. In 2020, several research institutes conducted extensive research using PEGylation technology.

Recent Developments

• In July 2022, The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended approval of doxorubicin hydrochloride (Celdoxome pegylated liposomal) for the treatment of metastatic breast cancer, advanced ovarian cancer, progressive multiple myeloma, and AIDS-related Kaposi's sarcoma.
• In February 2022, Merck KGaA announced the acquisition of Exelead, a biopharmaceutical CDMO specializing in PEGylated products and complex injectable formulations, including drug delivery technology based on lipid nanoparticles (LNPs).

Global PEGylated Proteins Market Scope

The PEGylated proteins market is segmented on the basis of product, protein type, application and end-use. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Consumable and Services
• PEGylation Kits and Reagents
• Monofunctional Linear PEGs
• Bifunctional PEGs
• Services
• Other Product Types

Protein Type

• Colony Stimulating Factors
• Interferons
• Erythropoietin
• mAbs
• Recombinant Factor VII
• Other Protein Type

 Application

• Cancer Treatment
• Hepatitis
• Chronic Kidney Diseases
• Hemophilia
• Multiple Sclerosis
• Gastrointestinal Disorders
• Others

 End-Use

• Pharmaceuticals
• Biotechnology Companies
• CROs
• Academic Research Institutes

PEGylated Proteins Market Regional Analysis/Insights

The PEGylated proteins market is analyzed and market size insights and trends are provided by country, product, protein type, application and end-use as referenced above.

The countries covered in the PEGylated proteins market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the PEGylated proteins market due to largest share of the market and growth in this market can be attributed to the increasing adoption of biologics drugs such as erythropoietin, monoclonal antibodies and others. 

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 owing to the growing incidence of cancer such as bladder, esophagus, liver, pancreas, and others, high presence of major manufacturers across the U.S. Furthermore, technological advancements and rising foreign investment.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and PEGylated Proteins Market Share Analysis

The PEGylated proteins market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to PEGylated proteins market.

Some of the major players operating in the PEGylated proteins market are:

• Thermo Fisher Scientific Inc. (U.S.)
• Merck KGaA (Germany)
• NOF CORPORATION (Japan)
• Jenkem Technology USA (U.S.)
• celares GmbH (Germany)
• Creative PEGWorks (U.S.)
• Quanta BioDesign, Ltd (U.S.)
• Biomatrik Inc (U.S.)
• Layson Bio Inc. (U.S.)
• IRIS BIOTECH GMBH (Germany)
• Valley Proteins, Inc. (U.S.)
• Enzon Pharamaceuticals, Inc (U.S.)
• Takeda Pharmaceuticals Company Limited (Japan)

Research Methodology: Global PEGylated Proteins Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report. 

SKU-56435